博瑞医药公告，公司董事长袁建栋提议使用自有资金以集中竞价交易方式回购公司股份，回购资金总额 不低于1000万元，不超过2000万元。回购股份将用于股权激励或员工持股计划，若3年内未使用完毕， 将予以注销。回购期限为董事会审议通过本次回购股份方案之日起12个月内。 ...

Group 1 - The stock prices of Mengke Pharmaceutical dropped over 10% [1] - Borui Pharmaceutical and Baicheng Pharmaceutical experienced declines of over 7% [1] - Other companies such as Yuekang Pharmaceutical, Kangchen Pharmaceutical, Yuandong Biological, and Fuxiang Pharmaceutical also saw significant drops in their stock prices [1]

科创医药ETF（588860）基金经理为史宝珖。 截至发稿，史宝珖累计任职时间3年300天，现任基金资产总规模33.04亿元，任职期间最佳基金回报 81.7%， 任职期间最差基金回报-27.72%。 9月25日，博瑞医药跌5.02%，截至发稿，报68.86元/股，成交4.67亿元，换手率1.57%，总市值291.12亿 元。博瑞医药股价已经连续4天下跌，区间累计跌幅23.54%。 资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28 栋，成立日期2001年10月26日，上市日期2019年11月8日，公司主营业务涉及研发和生产高端仿制药和 原创性新药。 从基金十大重仓股角度 数据显示，工银瑞信基金旗下1只基金重仓博瑞医药。科创医药ETF（588860）二季度持有股数12.99万 股，占基金净值比例为3.62%，位居第八大重仓股。根据测算，今日浮亏损失约47.28万元。连续4天下 跌期间浮亏损失289.89万元。 科创医药ETF（588860）成立日期2024年8月8日，最新规模1.93亿。今年以来收益45.78%，同类排名 936/4220；近一年收益70.79 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The industry is entering a new development phase driven by optimized procurement and innovation [3] - The raw material pharmaceutical sector is at a cyclical bottom, with companies actively transitioning to innovative drug development [5][8] - The vaccine sector is experiencing a decline in performance but is accelerating the layout of new technologies and products [6] - The medical services sector is leveraging AI technology to enhance efficiency and quality [7] Summary by Sections Raw Material Pharmaceutical Sector - The raw material pharmaceutical industry has faced a downturn for nearly four years, with prices of various products, such as sartans and heparins, reaching historical lows [5] - Revenue and net profit in the raw material pharmaceutical sector showed a downward trend in the first half of 2025 due to significant price drops in anti-infective products and increased R&D investments [5] - Companies like Huahai Pharmaceutical and Borui Pharmaceutical are focusing on innovative drug development, with several products in various clinical trial phases [5][68] Vaccine and Blood Products Sector - The vaccine industry is facing continuous performance decline due to a decrease in newborn numbers and changing competitive dynamics, although some companies are introducing new technologies and products [6] - The blood products sector is also experiencing a downturn, with revenue and net profit declining due to high inventory levels and suppressed demand from medical insurance [6][75] - The industry is expected to see increased consolidation as leading companies accelerate mergers and acquisitions [6][8] Medical Services Sector - The medical services sector's performance has declined due to DRGs and the consumption environment, but the application of AI technology is expected to enhance service quality and efficiency [7] - The core competitiveness of the medical services industry lies in acquiring and training quality doctors and hospital management [7] Investment Recommendations - The report suggests that companies in the raw material pharmaceutical sector are likely to enter a harvest period as they transition to innovative drugs [8] - The blood products sector is anticipated to accelerate consolidation, with significant mergers expected in the near future [8] - Recommended stocks include Federal Pharmaceutical, Pro Pharmaceutical, Guobang Pharmaceutical, and others, while benefiting stocks include Tianyu Co., Meinuo Pharma, and others [8]

Core Viewpoint - 博瑞医药's stock has experienced a significant decline, with a cumulative drop of 70% over the last 30 trading days, indicating severe abnormal trading fluctuations [2] Company Summary - 博瑞医药 announced that as of September 24, 2025, its closing price was 72.50 yuan per share [2] - The company's latest rolling price-to-earnings (P/E) ratio is 313.01, which is substantially higher than the average P/E ratio of 31.43 for the pharmaceutical manufacturing industry over the past month [2] - The company conducted a self-examination and confirmed that there are no undisclosed significant matters as of the announcement date [2] Industry Summary - The pharmaceutical manufacturing industry has an average rolling P/E ratio of 31.43, highlighting 博瑞医药's significantly elevated valuation compared to its peers [2]

格隆汇9月24日｜博瑞医药（维权）公告，公司股票连续30个交易日内收盘价格跌幅偏离值累计达到 70%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关 规定，属于股票交易严重异常波动情形。经公司自查，公司目前日常经营情况正常，未发生重大变化。 市场环境或行业政策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正 常。 ...

Core Viewpoint - 博瑞医药's stock has experienced a significant decline, with a cumulative drop of 70% over the last 30 trading days, indicating severe abnormal trading fluctuations [1] Company Summary - As of September 24, 博瑞医药's closing price was 72.5 yuan per share [1] - The latest rolling price-to-earnings (P/E) ratio for 博瑞医药 is 313.01, which is substantially higher than the average rolling P/E ratio of 31.43 for the pharmaceutical manufacturing industry over the past month [1] - 博瑞医药 has conducted a self-inspection and reported that its daily operations are normal, with no significant changes or fluctuations in production costs and sales [1] Industry Summary - The pharmaceutical manufacturing industry has an average rolling P/E ratio of 31.43, highlighting 博瑞医药's significantly elevated valuation compared to its peers [1]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-065 博瑞生物医药（苏州）股份有限公司 股票交易严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）股票连续 30 个交易日内收盘价格跌幅偏离值累计达到 70%，根据《上海证券交易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交 易严重异常波动情形。 经公司自查并发函向控股股东及实际控制人核实，截至本公告披露日， 公司不存在应披露而未披露的重大事项。 截至 2025 年 9 月 24 日，公司收盘价为 72.50 元/股。根据中证指数有限 公司发布的数据，截至 2025 年 9 月 23 日，公司最新滚动市盈率为 313.01 倍， 公司所处的医药制造业最近一个月平均滚动市盈率为 31.43 倍，公司市盈率显著 高于行业市盈率水平。公司特别提醒广大投资者，注意投资风险，理性决策，审 慎投资。 一、股票交易严重异常波动的具体情况 公司股票连续 ...

Core Insights - On September 24, a total of 31 stocks were identified with institutional activity, with 17 showing net buying and 14 showing net selling [1] Institutional Buying - The top three stocks with the highest net institutional buying were Huicheng Co., Beifang Huachuang, and Lixing Co., with net buying amounts of 152 million, 143 million, and 138 million respectively [1] Institutional Selling - The top three stocks with the highest net institutional selling were Borui Pharmaceutical, Changchuan Technology, and Kaimete Gas, with net outflow amounts of 471 million, 348 million, and 131 million respectively [1]

博瑞医药晚间公告，公司股票连续30个交易日内收盘价格跌幅偏离值累计达到70%，根据《上海证券交 易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易严重 异常波动情形。经公司自查，公司目前日常经营情况正常，未发生重大变化。市场环境或行业政策未发 生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩序正常。 ...